| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
To investigate the cytoprotective effect of geranylgeranylacetone (GGA) on retinal ganglion cell (RGC) degeneration using a normal tension glaucoma (NTG) mouse model, which lacks glutamate/aspartate transporter (GLAST) and demonstrates spontaneous RGC and optic nerve degeneration without elevated intraocular pressure (IOP).The number of RGC of GLAST+/- mice significantly decreased, as compared to that of littermate control mice. RGC loss was suppressed by administration of GGA in a dose-dependent manner. Following GGA administration, HSP70 was significantly up-regulated, and activities of caspase-9 and -3 were suppressed. HSP70 is a favorable target to suppress RGC degeneration, and thus GGA may be applicable for NTG as a promising therapeutics.
|
